Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing pozdeutinurad (AR882), a selective URAT1 inhibitor for the treatment of gout and tophaceous gout. The company was founded in 2018 by gout experts who previously led the clinical development of the first generation of urate-lowering therapies at Ardea Biosciences (acquired by AstraZeneca for $1.26B). Arthrosi has advanced its lead candidate through two fully enrolled Phase 3 clinical trials (REDUCE 1 and REDUCE 2) with data expected in 2026.
Arthrosi Therapeutics has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
25–50
Total Funding
$1.21B
5 rounds
Latest Valuation
$0.95B
Dec 14, 2025
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $1.21B across 5 rounds
Last updated 06-25-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Dec 14, 2025 | M&A exit (acquisition) | $950M | $0.95B | Swedish Orphan Biovitrum - acquirer |
| Jun 23, 2025 | Series E Press release | $153M | $0.8B | Prime Eight Capital |
| Jul 2023 | Series D | $75M | — | Not disclosed in free sources |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Entry · Series E
$800M
Jun 2025
Arthrosi Therapeutics today
$950M
Dec 2025 · latest mark
Arthrosi Therapeutics multiple
1.2x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Litain Yeh
CEO and Co-Founder
Shunqi Yan
Co-Founder
Robert Thomas Keenan
Chief Medical Officer
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.